• Who We Are
    • About Us
    • Contact Us
    • Member Partners
  • News
    • Latest News
    • Letters
    • Newsletters
    • Press Releases
    • Recent Events
  • The Issue
    • Interchangeable Biosimilars
    • Inflation Reduction Act (IRA)
    • Naming
    • Biologic Safety
    • BIO Principles
    • Non-Medical Switching
  • Policy
    • Australia
    • Canada
    • FDA
    • FDA Guidance
    • In the States
  • Resources
    • Surveys
    • Courses
    • Webinars
    • Approvals
    • Whitepapers
  • Blog
  • Videos

Safe Biologics

  • Safe Biologics

  • Who We Are
    • About Us
    • Contact Us
    • Member Partners
  • News
    • Latest News
    • Letters
    • Newsletters
    • Press Releases
    • Recent Events
  • The Issue
    • Interchangeable Biosimilars
    • Inflation Reduction Act (IRA)
    • Naming
    • Biologic Safety
    • BIO Principles
    • Non-Medical Switching
  • Policy
    • Australia
    • Canada
    • FDA
    • FDA Guidance
    • In the States
  • Resources
    • Surveys
    • Courses
    • Webinars
    • Approvals
    • Whitepapers
  • Blog
  • Videos
Background Image

Biotechnology Institute
Chesapeake Bioscience Education Foundation
Northern Virginia Life Sciences Communities
Virginia Bioscience Legislative Caucus
Virginia Biotechnology Association
Virginia Biotechnology Center
Virginia Council on Advanced Technology Skills
Virginia Department of Health
Virginia General Assembly
Virginia Tech Department of Biological Sciences
Virginia Tech Fralin Life Science Institute
Medical Society of Virginia
Office of Governor Bob McDonnell
University of Virginia Research Park
VCU Life Sciences

Latest News

New ASBM Infographic Tells Congress: “Proceed with Caution; Patients at Risk”

ASBM has released a new fact sheet explaining the risks posed by the Biosimilar Red Tape Elimination Act (BRTEA, S. 1954). Today, FDA evaluates each biosimilar individually before determining whether it is interchangeable—meaning it may be substituted at the pharmacy without the prescribing physician’s approval. BRTEA would eliminate that product-by-product scientific review and automatically deem […]

Read More

ASBM Supports Bipartisan SUSTAIN 340B Act

August 6, 2026 – ARLINGTON, VA The Alliance for Safe Biologic Medicines (ASBM) commends Senators Jerry Moran (R-KS), Tammy Baldwin (D-WI), Shelley Moore Capito (R-WV), Tim Kaine (D-VA), John Boozman (R-AR), and John Hickenlooper (D-CO) for introducing the bipartisan Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future of 340B Act, […]

Read More

Andrew Spiegel and Marcia Horn: MFN Could Cost Patients Cancer Breakthroughs

Read More

logo logo logo
logo

The Alliance for Safe Biologic Medicines (ASBM) is a diverse coalition of stakeholders working worldwide to shape policies that reflect the best interests of patients, ensuring access to lifesaving and life-enhancing medicines while fostering innovation in healthcare.

Contact Us

Who we are
  • About Us
  • Contact Us
  • Member Partners
  • International Advisory Board
News
  • Latest News
  • Letters
  • Newsletter
  • Press Releases
  • Recent Events
The Issue
  • Interchangeable Biosimilars
  • Inflation Reduction Act (IRA)
  • Naming
  • Substitution Policy
  • Biologic Safety
  • BIO Principles
Policy
  • Australia
  • Canada
  • European Union
  • FDA
  • FDA Guidance
  • In the States
Resources
  • Surveys
  • Courses
  • Webinars